Another therapy recently approved by the FDA is the combination of atezolizumab with BRAF inhibitor vemurafenib and MEK inhibitor cobimetinib, resulted in safe tolerability and prolonged progression-free cell survival in melanoma patients [6]. This evidence concerns the gene MAP2K7 and melanoma.